Travere Just Got the FDA Approval It Has Been Waiting Years For
Filspari is now the first and only approved drug for FSGS.
Travere Therapeutics (NASDAQ: TVTX) announced Monday that the U.S. Food and Drug Administration has granted full approval for Filspari (sparsentan) to treat focal segmental glomerulosclerosis (FSGS), a rare kidney disease that scars the organ's filtering units and often leads to kidney failure. The approval makes Filspari the first and only FDA-approved medicine for FSGS, expanding the drug's reach beyond its existing indication in IgA nephropathy (IgAN) into a second rare kidney disease. Shares rose approximately 6 percent on the news.
The decision followed a delayed review: the FDA extended its timeline in January to seek additional clinical data. That the agency ultimately granted full approval (rather than accelerated approval, which carries post-marketing confirmation requirements) suggests the Phase 3 DUPLEX trial data were persuasive enough to clear the higher bar.
The clinical case
The Phase 3 DUPLEX Study, the largest head-to-head interventional trial in FSGS to date, enrolled 371 patients aged 8 to 75. In the overall population, patients treated with Filspari experienced a statistically significant 46 percent reduction in proteinuria (protein leakage into the urine, a key marker of kidney damage) from baseline to Week 108, compared to 30 percent for patients on maximum-dose irbesartan, the active control.
In the subset of patients without nephrotic syndrome, the results were even stronger: a 48 percent reduction in proteinuria for Filspari versus 27 percent for irbesartan (p-value of 0.0075). That subgroup is the approved population, and the label aligns with KDIGO clinical practice guidelines for managing FSGS.
Today marks a historic milestone for people living with FSGS, who for the first time have an FDA-approved medicine for this rare and devastating condition.
Kirk Campbell, M.D., president of the National Kidney Foundation and chief of the Division of Renal-Electrolyte and Hypertension at the University of Pennsylvania's Perelman School of Medicine, called the approval "an important new option" for patients who have long relied on off-label therapies such as long-term steroids.
The commercial math
The approval expands Filspari's total addressable population to more than 100,000 patients in the U.S. across both FSGS and IgAN, according to the company. Travere estimates the FSGS-specific addressable population (patients without nephrotic syndrome) at more than 30,000 individuals. FSGS is estimated to affect more than 40,000 patients in the U.S. overall, with a similar prevalence in Europe.
Filspari is currently priced at approximately $9,900 per month (roughly $170,000 per year) for IgAN. But the FSGS indication requires a higher dose, and Jefferies analyst Maury Raycroft told Reuters he expects the FSGS price to be "approximately 2x of what they're charging for IgAN." Jefferies projects peak sales of $961 million by 2033 for the FSGS indication alone.
Filspari generated $103.3 million in U.S. net product sales in the quarter ended December 31, 2025, according to the company's investor relations page. Total U.S. net product sales (including Thiola for cystinuria) were $127 million in the same period, with 908 new patient start forms for Filspari.
To be sure, the commercial ramp will not be instantaneous. Filspari carries boxed warnings for liver damage and birth defects, and the drug's Risk Evaluation and Mitigation Strategies (REMS) program requires liver monitoring. Those requirements add friction to the prescribing process. But the company said Filspari would be available for nephrologists to immediately prescribe to FSGS patients, and the existing Travere TotalCare support program is already in place to manage insurance and monitoring logistics.
The competitive landscape
Filspari's first-mover advantage in FSGS is real but not permanent. Swiss drugmaker Novartis is testing its drug atrasentan in a mid-stage trial in FSGS patients. Novartis recently published IgAN data in the New England Journal of Medicine showing its complement inhibitor Fabhalta slowed kidney function decline by 49.3 percent, underscoring the company's commitment to the nephrology space. Any successful Phase 3 readout from Novartis would introduce direct competition in a market Travere currently has to itself.
Travere obtained rights to sparsentan from Ligand Pharmaceuticals in 2012 under a licensing agreement that entitles Ligand to milestone payments and a 9 percent royalty on global sales. That royalty is a meaningful drag on margins as the drug scales.
| TVTX | +6.0% | FDA approved Filspari for FSGS |
| LGND | +4.2% | Licensor of sparsentan; receives 9% royalty on sales |
| VERA | -3.0% | Rival nephrology-focused biotech (atacicept for IgAN) |
| CORT | +3.3% | Rare disease biotech peer |
| SRRK | -0.9% | Rare disease biotech peer |
The analyst view
Wall Street's consensus on TVTX is firmly bullish: 15 of 18 analysts rate the stock a Buy, with three Holds and no Sells. The median price target sits at $54, implying roughly 76 percent upside from the current price near $30.70. JP Morgan maintained its Overweight rating in late March, though it lowered its price target from $44 to $41.
The stock has already run considerably from its 52-week low of $13.88, and at $30.70 it trades at approximately 44 times forward earnings. The FSGS approval was not a surprise (the DUPLEX data were public), but the full approval designation and the immediate prescribing availability remove two sources of uncertainty that had weighed on the stock.
What comes next
The near-term catalyst is execution: how quickly Travere can convert the FSGS approval into new patient starts and revenue. The company reports earnings on or around April 30, which will provide the first window into early FSGS prescribing trends (though meaningful revenue contribution will likely take several quarters). Travere also has pegtibatinase, an enzyme replacement therapy for classical homocystinuria, in its clinical pipeline.
The medium-term question is whether Filspari can reach the peak sales figures analysts are projecting. At $961 million in FSGS alone (per Jefferies), plus the existing IgAN franchise, Travere would be generating well over $1 billion in annual revenue from a single molecule. That would represent a transformation for a company with a current market capitalization of approximately $2.8 billion. Only time will tell whether the commercial ramp matches the clinical promise, but for the first time, Travere has two approved indications generating revenue from the same drug.
Professional-grade stock research in your terminal
Get real-time alerts and deeper analysis on events like this.